Literature DB >> 21414657

Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen.

Shilpa Vishwanath, Fuad M Baroody, Mohamad R Chaaban, Marcella deTineo, Kenneth H Lasser, Elliot C Lasser, Robert M Naclerio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21414657     DOI： 10.1016/j.jaci.2011.02.024

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  1 in total

1.  Iodixanol nasal solution reduces allergic rhinoconjunctivitis signs and symptoms in Allergen BioCube®: a randomized clinical trial.

Authors:  Paul J Gomes; Mark B Abelson; Linda Stein; Erik Viirre; J Ernest Villafranca; Elliott C Lasser
Journal:  J Asthma Allergy       Date:  2019-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.